Stay updated with breaking news from Interim Head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
06.12.2022 - Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major ... Seite 1
The EMA has accepted the marketing authorisation application for tofersen, which could be the first treatment for a rare genetic cause of ALS.
Animal Abusers win thru censorship in a free-speech North Carolina student newspaper. The almighty dollar is more powerful than University policy.
SOD1-ALS is a rare, genetic form of ALS,1 comprising approximately 2% of people with ALS2If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. ... | December 5, 2022
WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday that the European Medicines Agency or EMA has accepted the Marketing Authorization Application or MAA for review of tofersen to treat rare